MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/cco-25-35

Медицинская библиотека · Chinese clinical oncology · 2025

New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative review.

Di Costanzo Fabrizio, Parisi Iolanda Santa, Neola Giuseppe, Flauto Fabiano, Pecoraro Giovanna, Formisano Luigi, Conteduca Vincenza, Mercinelli Chiara, Maiorano Brigida Anna, Banna Giuseppe Luigi, Maffezzoli Michele, Buti Sebastiano, Fornarini Giuseppe, Rebuzzi Sara Elena, Campobasso Davide, Chandler Robert, Oing Christoph, Rescigno Pasquale

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

Most of newly diagnosed prostate carcinomas (PCas) present as non-metastatic disease, with approximately 15% of them presenting with characteristics predicting for a high-risk of relapse. Hence, specific focus has to be placed on patients affected by localised or locally advanced disease, whose chances of cure are notably higher than those of patients in advanced settings. With androgen receptor pathway inhibitors (ARPIs) and docetaxel chemotherapy improving treatment efficacy outcomes when compared to traditional androgen deprivation therapy (ADT) in the metastatic disease, clinical trials are currently investigating the activity of ARPI for clinical management of localised or locally advanced prostate patients, with the aim of preventing the cancer from spreading systemically. To provide further insight into the biological and clinical rationale of an early treatment intensification, here we review and enlist promising studies on the treatment of localised, locally advanced, and biochemically relapsed disease. Finally, we briefly review the latest experimental treatments for these early stages-including novel agents and combinations which are believed to shape the future practice.

METHODS

PubMed and MEDLINE databases were searched for trials focusing on the treatment of localised/locally advanced PCa, and which included the use of second-generation ARPIs. Also, proceedings from major oncology and uro-oncology meetings were screened.

KEY CONTENT AND FINDINGS: Our analysis has not yielded significant results supporting the implementation of second-generation ARPIs in the perioperative or neoadjuvant treatment of localised PCa. However, the data suggest these drugs may offer benefits in the adjuvant setting, following both radical prostatectomy (RP) and primary radiotherapy (RT).

CONCLUSIONS

The design of clinical trials that explore surrogate endpoints like metastasis-free survival (MFS) or employing multi-arm trials with genomic testing could facilitate further advancements in this field, as well as research on combining ARPI treatment with inhibition of other pathways or exploiting the immune response beyond PD-1/CD276.

Для цитирования: Di Costanzo Fabrizio, Parisi Iolanda Santa, Neola Giuseppe, Flauto Fabiano, Pecoraro Giovanna, Formisano Luigi, Conteduca Vincenza, Mercinelli Chiara, Maiorano Brigida Anna, Banna Giuseppe Luigi, Maffezzoli Michele, Buti Sebastiano, Fornarini Giuseppe, Rebuzzi Sara Elena, Campobasso Davide, Chandler Robert, Oing Christoph, Rescigno Pasquale. New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative review.. Chinese clinical oncology. 2025. DOI: 10.21037/cco-25-35.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.